Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.5K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

4.3K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.3K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

18.2K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
18.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

853
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
853

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapid Histone Post-Translational Modification Analysis Using Alternative Proteases and Tandem Mass Tags.

Analytical chemistry·2026
Same author

Single-molecule nanophotonic resolution of binding dynamics from apo to fully liganded for a cyclic nucleotide-gated ion channel in cell-derived vesicles.

bioRxiv : the preprint server for biology·2026
Same author

An atomic interaction conserved for over 600 million years gates inhibitory neurotransmission.

bioRxiv : the preprint server for biology·2026
Same author

Open-State Dynamics and Allosteric Modulation of the α1β3γ2 GABA<sub>A</sub> Receptor Stabilized by L9'T/S Substitutions.

Journal of chemical information and modeling·2026
Same author

Differences in immune cell profiles around the time of islet autoimmunity seroconversion in children with and without type 1 diabetes.

BMJ open diabetes research & care·2026
Same author

Translational evidence for increased central amygdala IL-6 activity in alcohol dependence.

Journal of neuroinflammation·2026

Related Experiment Video

Updated: Feb 26, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.3K

Novel Molecule Exhibiting Selective Affinity for GABAA Receptor Subtypes.

Cecilia M Borghese1, Melissa Herman2,3, Lawrence D Snell4

  • 1The University of Texas at Austin, Waggoner Center for Alcohol and Addiction Research, Austin, TX, 78712, USA.

Scientific Reports
|July 26, 2017
PubMed
Summary

A novel compound, DCUK-OEt, acts as a positive allosteric modulator for specific brain gamma-aminobutyric acid type A (GABAA) receptors. This discovery holds potential for treating alcohol dependence by targeting central amygdala neurons.

More Related Videos

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
07:51

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors

Published on: November 14, 2014

18.0K
A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
04:48

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate

Published on: July 10, 2018

9.8K

Related Experiment Videos

Last Updated: Feb 26, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.3K
Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
07:51

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors

Published on: November 14, 2014

18.0K
A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
04:48

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate

Published on: July 10, 2018

9.8K

Area of Science:

  • Neuropharmacology
  • Molecular Neuroscience
  • Drug Discovery

Background:

  • Gamma-aminobutyric acid type A (GABAA) receptors are crucial for inhibitory neurotransmission in the brain.
  • Modulators of GABAA receptors are sought for therapeutic applications, including treatment for alcohol dependence.
  • Existing GABAA receptor modulators exhibit diverse subunit specificities and binding sites.

Purpose of the Study:

  • To identify novel aminoquinoline derivatives with activity at various brain receptors.
  • To characterize the specific GABAA receptor subtypes modulated by the identified compound.
  • To investigate the potential therapeutic relevance of the compound for alcohol dependence.

Main Methods:

  • Radioligand binding experiments to screen aminoquinoline derivatives.
  • Electrophysiological studies to assess positive allosteric modulation of GABA currents.
  • Subunit composition analysis to determine receptor subtype specificity.
  • Simulated molecular docking to predict binding site.
  • Brain slice electrophysiology in the central amygdala to evaluate effects on tonic and phasic currents.

Main Results:

  • DCUK-OEt, an aminoquinoline derivative, demonstrated micromolar affinity for GABAA receptors.
  • DCUK-OEt acted as a positive allosteric modulator (PAM) on specific GABAA receptor subtypes (e.g., α1β2γ2, α1β3γ2, α5β3γ2, α1β3δ), but not others.
  • Flumazenil did not block DCUK-OEt modulation, suggesting a distinct binding site, potentially at the α+/β- subunit interface.
  • In central amygdala slices, DCUK-OEt selectively increased extrasynaptic tonic current mediated by α1-containing GABAA receptors, without affecting phasic currents.

Conclusions:

  • DCUK-OEt represents a novel chemical structure acting as a selective PAM at particular GABAA receptor subtypes.
  • Its distinct subunit and binding site profile differentiates it from known GABAergic modulators.
  • Given its action on central amygdala neurons implicated in alcohol dependence, DCUK-OEt warrants further investigation for alcoholism treatment.